Skip to main content
main-content

26-09-2017 | ESMO 2017 | Video

ESMO 2017: BRIM8 trial findings

Presenter Karl Lewis outlines the findings for adjuvant vemurafenib versus placebo in patients at high risk of recurrence after resection of BRAF V600+ advanced or metastatic melanoma.